83440-03-3

Basic information

• Product Name: N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE
• Synonyms: SG 209;N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE;2-[(3-Pyridinylcarbonyl)amino]ethyl acetate;Acetic acid 2-(3-pyridinylcarbonylamino)ethyl ester;N-(2-Acetyloxyethyl)-3-pyridinecarboxamide
• CAS NO: 83440-03-3
• Molecular Formula: C10H12N2O3
• Molecular Weight: 208.21
• Mol File: 83440-03-3.mol

Chemical Properties

• Boiling Point: 430.7°C at 760 mmHg
• Flash Point: 214.3°C
• Appearance: tan/solid
• Density: 1.182g/cm³
• Vapor Pressure: 1.27E-07mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: −20°C
• Solubility: DMSO: ~24 mg/mL, soluble
• CAS DataBase Reference: N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE(83440-03-3)
• EPA Substance Registry System: N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE(83440-03-3)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 83440-03-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE is used as a pharmaceutical agent for its ability to inhibit the release of TNFα from lymphocyte cell lines and peripheral blood lymphocytes. This makes it a potential candidate for the treatment of inflammatory and immune-related conditions.
Used in Cardiovascular Applications:
As a potassium channel opener and nitric oxide donor, N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE can be used in the treatment of cardiovascular diseases, such as angina pectoris, by improving blood flow and reducing the workload on the heart.
Used in Drug Delivery Systems:
N-[2-(ACETOXY)ETHYL]-3-PYRIDINECARBOXAMIDE can be incorporated into drug delivery systems to enhance its therapeutic efficacy and bioavailability, making it a promising candidate for the development of novel pharmaceutical formulations.

Biological Activity

Analog of nicorandil . A nitrate-free coronary vasodilator; activates K + channels.

InChI:InChI=1/C10H12N2O3/c1-8(13)15-6-5-12-10(14)9-3-2-4-11-7-9/h2-4,7H,5-6H2,1H3,(H,12,14)

Upstream product

• 6265-73-2 N-(2-hydroxyethyl)nicotinamide 
• 75-36-5 acetyl chloride 

Relevant articles and documents

NOVEL DRUGS FOR DEMENTIA

The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain or central nervous system. The cysteine protease inhibitor inhibits cysteine proteases upon release from the prodrug. Cysteine protease inhibitors are effective for treating dementia, Alzheimer's disease and vascular dementia. Targeting the brain or central nervous system offers significant advantages in treating these conditions and diseases. A preferred CDS prodrug is a dihydrotrigoneline CDS moiety coupled to an epoxysuccinyl peptide cysteine protease inhibitor moiety.

Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof

Novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular and neurovascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, inflammatory disorders, immunological disorders, oxidative stress, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification. Also disclosed is a method for preparation of the compounds of general formula (I) and pharmaceutical composition containing one or more compounds as defined above as active ingredients. Also disclosed is a method of treatment of a diabetic patient by administering the compounds as defined above, either singly or in combination with drugs for antidiabetic therapy.